Dark

Check out our API

CNST
Constellation Pharmaceuticals, Inc.
stock NASDAQ

Inactive

Jul 14, 2021

33.99USD+0.059%(+0.02)1,314,791

Pre-market

0.00USD-100.000%(-33.97)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 1, 2021

10:36AM EDT MorphoSys AG (MOR) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for its tender offer for Constellation Pharmaceuticals Inc. (CNST). RTTNews

Jun 23, 2021

12:01PM EDT SHAREHOLDER ALERT: WeissLaw LLP Reminds KIN, FMBI, SLCT, and CNST GlobeNewswire Inc

Jun 17, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 17, 2021 Benzinga

09:20AM EDT RBC Capital Downgrades Constellation to Sector Perform, Lowers Price Target to $34 Benzinga

Jun 16, 2021

12:21PM EDT SHAREHOLDER ALERT: WeissLaw LLP Reminds FMBI, SLCT, CNST, and GlobeNewswire Inc

Jun 11, 2021

09:19AM EDT Constellation Pharmaceuticals Provides Update From Ongoing MANIFEST Study Of Pelabresib RTTNews

09:05AM EDT Constellation Pharmaceuticals Highlights Presentation Of Three Posters Relating To MANIFEST Trial Of Pelabresib At European Hematology Association Annual Meeting Benzinga

09:00AM EDT -- Translational data support the disease-modifying potential of pelabresib -- Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment -- Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups GlobeNewswire Inc

Jun 9, 2021

01:04PM EDT SHAREHOLDER ALERT: WeissLaw LLP Reminds COHR, FMBI, SLCT, and CNST GlobeNewswire Inc

Jun 4, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021 Benzinga

09:22AM EDT Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting Benzinga

09:00AM EDT -- Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapy -- Oral, once-daily 350mg dose selected for Phase 2 -- Enrollment of tumor-specific expansion cohorts is ongoing GlobeNewswire Inc

06:50AM EDT Jefferies Downgrades Constellation to Hold, Lowers Price Target to $34 Benzinga

Jun 3, 2021

12:06PM EDT Truist Securities Downgrades Constellation to Hold, Lowers Price Target to $34 Benzinga

10:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021 Benzinga

08:37AM EDT Cowen & Co. Downgrades Constellation to Market Perform Benzinga

08:23AM EDT The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout Benzinga

Jun 2, 2021

02:39PM EDT Mid-Afternoon Market Update: Constellation Pharmaceuticals Surges Following Acquisition News; Protalix BioTherapeutics Shares Slide Benzinga

12:30PM EDT Mid-Day Market Update: Crude Oil Rises 1%; iRhythm Technologies Shares Plunge Benzinga

10:24AM EDT Mid-Morning Market Update: Markets Open Higher; Advance Auto Parts Profit Tops Estimates Benzinga

09:10AM EDT MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma Benzinga

09:06AM EDT (CNST Alert) Johnson Fistel Investigates Proposed Sale of Constellation PR Newswire

08:13AM EDT Royalty Pharma plc (RPRX) said that it has reached a $2.025 billion strategic funding partnership with MorphoSys AG (MOR), as part of MorphoSys' $1.7 billion acquisition of Constellation Pharmaceuticals (CNST). RTTNews

07:44AM EDT Royalty Pharma Announces $2.025B Funding Partnership With MorphoSys To Enable MorphoSys' Acquisition Of Constellation; Royalty To Acquire Rights To Receive Royalties On Multiple Products Benzinga

07:40AM EDT Royalty Pharma Announces $2.025 Billion Strategic Funding GlobeNewswire Inc

07:28AM EDT MorphoSys To Acquire Constellation Pharmaceuticals For $34/Shr In Cash RTTNews

07:25AM EDT MorphoSys to Acquire Constellation Pharmaceuticals Business Wire

May 10, 2021

07:09AM EDT Constellation Pharmaceuticals Sees Current Cash, Cash Equivalents, Marketable Securities Will Fund Operations Into Mid-2023 Benzinga

07:08AM EDT Constellation Q1 EPS $(0.84) Misses $(0.79) Estimate Benzinga

07:00AM EDT -- Dosing underway in the Phase 3 MANIFEST-2 clinical trial -- Recommended Phase 2 dose determined for CPI-0209 and first patient dosed in the Phase 2 expansion cohorts -- Upcoming data presentation at ASCO supports the best-in-class target engagement potential of CPI-0209 GlobeNewswire Inc

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

Apr 27, 2021

11:30AM EDT Constellation Pharmaceuticals to Host Conference Call to Discuss GlobeNewswire Inc

Feb 24, 2021

02:32PM EST Mid-Afternoon Market Update: Dow Rises Over 400 Points; Owens & Minor Shares Surge On Upbeat Q4 Results Benzinga

12:12PM EST Mid-Day Market Update: US Stocks Turn Higher; Systemax Shares Fall Following Q4 Earnings Benzinga

07:05AM EST Constellation Q4 EPS $(0.79) Misses $(0.76) Estimate Benzinga

07:00AM EST Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced itsfourth-quarter 2020 financial results and provided a business update. GlobeNewswire Inc

03:35AM EST Earnings Scheduled For February 24, 2021 Benzinga

Feb 19, 2021

04:00PM EST Constellation Pharmaceuticals to Participate in the 10th Annual GlobeNewswire Inc

Feb 18, 2021

10:00AM EST Constellation Pharmaceuticals to Host Conference Call to Discuss GlobeNewswire Inc

Jan 25, 2021

12:33PM EST Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation Benzinga

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 25, 2021 Benzinga

06:46AM EST BMO Capital Upgrades Constellation to Outperform, Raises Price Target to $50 Benzinga

Jan 7, 2021

09:30AM EST Constellation Pharmaceuticals Appoints Brendan Delaney as Chief GlobeNewswire Inc

Jan 6, 2021

10:00AM EST Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare GlobeNewswire Inc

Dec 6, 2020

08:00AM EST -- 67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeks -- CPI-0610 demonstrated activity, bothas a monotherapy and asadd on to ruxolitinib,in second-line or later settings -- Translational data supportspotentialdisease-modifying effects of CPI-0610 GlobeNewswire Inc

Nov 29, 2020

08:59AM EST The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga

Nov 23, 2020

01:01PM EST Constellation Pharmaceuticals To Host Analyst/Investor Event To Discuss Update Of MANIFST Clinical Trial For CPI-0610 Presented At ASH Meeting Benzinga

01:00PM EST Constellation Pharmaceuticals to Host Analyst / Investor Event to GlobeNewswire Inc

Oct 29, 2020

07:49AM EDT Constellation Q3 EPS $(0.71) Misses $(0.68) Estimate Benzinga

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

07:01AM EDT -- MANIFEST data update planned for the American Society of Hematology (ASH) meeting in December GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 19, 2020

02:00PM EDT Constellation Pharmaceuticals to Host Conference Call to Discuss GlobeNewswire Inc

Sep 9, 2020

03:00PM EDT Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in upcoming virtual investor conferences. Jigar Raythatha, CEO, will present at: GlobeNewswire Inc

Sep 8, 2020

10:10AM EDT Benzinga's Top Upgrades, Downgrades For September 8, 2020 Benzinga

06:40AM EDT Oppenheimer Downgrades Constellation to Perform Benzinga

Sep 3, 2020

10:21AM EDT Benzinga's Top Upgrades, Downgrades For September 3, 2020 Benzinga

07:14AM EDT Brookline Capital Initiates Coverage On Constellation with Buy Rating, Announces Price Target of $33 Benzinga

Aug 6, 2020

11:38AM EDT BMO Capital Maintains Market Perform on Constellation, Lowers Price Target to $28 Benzinga

Aug 5, 2020

08:07AM EDT Constellation Q2 EPS $(0.70) Misses $(0.63) Estimate Benzinga

07:00AM EDT -- Constellation has aligned with the FDA on the design of MANIFEST-2, the pivotal Phase 3 clinical trial for CPI-0610 expected to begin in 2H20 -- Constellation plans to explore additional indications for CPI-0610 GlobeNewswire Inc

04:21AM EDT Earnings Scheduled For August 5, 2020 Benzinga

Jul 31, 2020

12:00PM EDT Constellation Pharmaceuticals to Host Conference Call to Discuss GlobeNewswire Inc

Jul 20, 2020

09:52AM EDT Jefferies Maintains Buy on Constellation, Lowers Price Target to $53 Benzinga

Share